论文部分内容阅读
目的：评价血管紧张素转换酶抑制剂（ＡＣＥＩ）在风湿性心瓣膜病心力衰竭（风心病心衰）中的临床应用效果。方法：２７例风心病心衰病人除常规治疗外加用小剂量卡托普利（１２．５～５０ｍｇ／ｄ），并与其他２４例常规治疗病人对照。结果：卡托普利改善了风心病心衰病人的心功能及预后，提高了生活质量，并使其左心房内径缩小。结论：血管紧张素转换酶抑制剂是能改善风心病心衰病人预后、提高其生活质量的血管扩张剂，对伴有瓣膜关闭不全的病人效果更好。
Objective: To evaluate the clinical effect of angiotensin converting enzyme inhibitor (ACEI) in patients with rheumatic valvular heart failure (rheumatic heart failure). Methods: A total of 27 patients with heart disease of rheumatic heart disease were treated with low-dose captopril (12.5-50 mg / d) in addition to conventional treatment and compared with 24 other conventional patients. RESULTS: Captopril improved cardiac function and prognosis in patients with rheumatic heart failure, improved quality of life, and reduced the diameter of the left atrium. CONCLUSION: Angiotensin-converting enzyme inhibitors are vasodilators that improve the prognosis and improve the quality of life in patients with rheumatic heart failure, and are more effective in patients with valvular insufficiency.